BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)

N/A

Report date: 2024/04/10 16:39:55

Base Information

Drug NameBCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics)
Drug Alias NameCBG002 CAR-T细胞注射液CBG-002 CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarbiogene Therapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of MedicineCarbiogene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A